Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study-Reference-Cited by-同舟云学术

Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study

Published:2021-09 Issue: Volume:43 Page:24-30
ISSN:2667-0895
Container-title:Atherosclerosis Plus
language:en
Short-container-title:Atherosclerosis Plus

Author:

Ray Kausik K.,Haq Inaam,Bilitou Aikaterini^ORCID,Aguiar Carlos,Arca Marcello^ORCID,Connolly Derek L.^ORCID,Eriksson Mats,Ferrières Jean,Hildebrandt Per,Laufs Ulrich,Mostaza Jose M.,Nanchen David^ORCID,Rietzschel Ernst,Strandberg Timo,Toplak Hermann^ORCID,Visseren Frank L.J.,Catapano Alberico L.^ORCID

Publisher

Elsevier BV

Reference24 articles.

1. European cardiovascular disease statistics 2017;Wilkins,2017

2. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020

3. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials;Mihaylova;Lancet,2012

4. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol;Grundy;J Am Coll Cardiol,2019

5. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study;Ray;Eur J Prevent Cardiol,2020

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. When “old” lipid lowering therapies not should be discontinued;Clínica e Investigación en Arteriosclerosis;2024-09

2. Real-world evidence evaluation of LDL-C in hospitalized patients: a population-based observational study in the timeframe 2021–2022;Lipids in Health and Disease;2024-07-24

3. Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy;Advances in Therapy;2024-07-04

4. Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study;Pharmacy;2024-07-03

5. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study;European Journal of Preventive Cardiology;2024-06-11